Market Overview

Teva Vs Mylan: Wells Fargo Weighs In

Teva Vs Mylan: Wells Fargo Weighs In
Related TEVA
This Day In Market History: UN Partitions Palestine For Independent Jewish State
9 Policy Catalysts For Health Care Investors To Watch Before Year's End
Mylan: Blank Check On Growth? (Seeking Alpha)
Related MYL
The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Mylan: Blank Check On Growth? (Seeking Alpha)

The past year has been a rollercoaster ride for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) and its investors. But even with the stock down 48.6 percent in the past year, investors may have more downside ahead in 2018, according to Wells Fargo. 

The Analyst

Wells Fargo analyst David Maris downgraded Teva from Market Perform to Underperform and raised the price target from $12 to $17.

The Thesis

The market got it right when Teva shares initially tanked following major guidance and dividend cuts last year, Maris said in a note. (See the analyst's track record here.) 

But the stock has inexplicably risen roughly 80 percent from its 2017 lows, and Maris said there’s no fundamental justification for the move. In the downgrade note, Maris said dip buyers are misguided.

“We expect other generic Copaxones will emerge in 2018, pricing pressures will remain and Teva’s debt will be downgraded, and as such, we think the recent rally is a good time to sell shares and reassess things after Teva provides its 2018 update Feb. 8, 2018," the analyst said. 

In addition to the downgrade, Maris reduced his 2018 EPS estimate for Teva from $2.86 to $2.68, significantly lower than $3 consensus. The new estimates comes after Teva announced $3 billion in cost cuts over the next several years. Maris said he is not optimistic that these costs cuts and layoffs will have a meaningful impact on Teva’s bottom line given the company's number of fixed costs. 

While Teva may look like a better value than competitor Mylan NV (NASDAQ: MYL), Maris said Teva's long list of challenges and its massive debt load make Mylan a better play today. 

Price Action

Teva stock was down more than 2 percent at the time of publication Friday afternoon. 

Related Links:

A Look At Teva's Big Week

Credit Suisse Upgrades Teva After Job Cuts Announced

Latest Ratings for TEVA

Nov 2018Morgan StanleyUpgradesEqual-WeightOverweight
Nov 2018Bank of AmericaMaintainsUnderperformUnderperform
Oct 2018Goldman SachsMaintainsBuyBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Davis MarisAnalyst Color Biotech Downgrades Price Target Top Stories Analyst Ratings General Best of Benzinga


Related Articles (MYL + TEVA)

View Comments and Join the Discussion!

Latest Ratings

DESPKeyBancInitiates Coverage On0.0
MELIKeyBancInitiates Coverage On0.0
ABTCredit SuisseInitiates Coverage On82.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Argus Shares Eli Lilly's Optimism, Upgrades To Buy

7 Top Picks For 2018 And Their Corresponding ETFs